Instituto Mexicano Del Seguro Social

Ecatepec, Mexico

Instituto Mexicano Del Seguro Social

Ecatepec, Mexico
SEARCH FILTERS
Time filter
Source Type

Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: SC1-PM-22-2016 | Award Amount: 15.59M | Year: 2016

ZIKAlliance is a multidisciplinary project with a global One Health approach, built: on a multi-centric network of clinical cohorts in the Caribbean, Central & South America; research sites in countries where the virus has been or is currently circulating (Africa, Asia, Polynesia) or at risk for emergence (Reunion Island); a strong network of European and Brazilian clinical & basic research institutions; and multiple interfaces with other scientific and public health programmes. ZIKAlliance will addrees three key objectives relating to (i) impact of Zika virus (ZIKV) infection during pregnancy and short & medium term effects on newborns, (ii) associated natural history of ZIKV infection in humans and their environment in the context of other circulating arboviruses and (iii) building the overall capacity for preparedness research for future epidemic threats in Latin America & the Caribbean. The project will take advantage of large standardised clinical cohorts of pregnant women and febrile patients in regions of Latin America and the Caribbean were the virus is circulating, expanding a preexisting network established by the IDAMS EU project. I will also benefit of a very strong expertise in basic and environmental sciences, with access to both field work and sophisticated technological infrastructures to characterise virus replication and physiopathology mechanisms. To meet its 3 key objectives, the scientific project has been organised in 9 work packages, with WP2/3 dedicated to clinical research (cohorts, clinical biology, epidemiology & modeling), WP3/4 to basic research (virology & antivirals, pathophysiology & animal models), WP5/6 to environmental research (animal reservoirs, vectors & vector control) , WP7/8 to social sciences & communication, and WP9 to management. The broad consortium set-up allow gathering the necessary expertise for an actual interdisciplinary approach, and operating in a range of countries with contrasting ZIKV epidemiological status.


Pi-Sunyer X.,Columbia University | Astrup A.,Copenhagen University | Fujioka K.,Scripps Research Institute | Greenway F.,Louisiana State University | And 7 more authors.
New England Journal of Medicine | Year: 2015

BACKGROUND Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagonlike peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P<0.001, with last-observation-carried-forward imputation). A total of 63.2% of the patients in the liraglutide group as compared with 27.1% in the placebo group lost at least 5% of their body weight (P<0.001), and 33.1% and 10.6%, respectively, lost more than 10% of their body weight (P<0.001). The most frequently reported adverse events with liraglutide were mild or moderate nausea and diarrhea. Serious events occurred in 6.2% of the patients in the liraglutide group and in 5.0% of the patients in the placebo group. CONCLUSIONS In this study, 3.0 mg of liraglutide, as an adjunct to diet and exercise, was associated with reduced body weight and improved metabolic control. (Funded by Novo Nordisk; SCALE Obesity and Prediabetes NN8022-1839 ClinicalTrials.gov number, NCT01272219.). Copyright © 2015 Massachusetts Medical Society.


Patent
Institute Pasteur Paris, Instituto Mexicano Del Seguro Social and French National Center for Scientific Research | Date: 2015-04-08

The invention relates to an in vitro method for investigating the level of mtDNA in a biological sample removed from a patient susceptible of suffering from a gastric cancer condition or susceptible of suffering of condition(s) susceptible to evolve in a gastric cancer condition by pooling said biological sample into categories, upon determination of the level of mtDNA in said biological sample. The invention also relates to a method for in vitro monitoring or diagnosing the health status of a patient susceptible of suffering from a gastric cancer condition or suffering from a gastric cancer condition or susceptible of suffering of condition(s) susceptible to evolve in a gastric cancer condition, comprising a step of measuring, in parallel to the investigation of the level of mtDNA, the level of any one of the following parameters: cytokine IL-8, platelet count (PLT) and/or mean platelet volume (MPV) and/or percentage of large platelets (LPLT), inflammatory markers such as IL-6 and/or IL-23, or any combination of these parameters, and concluding about the health status of the tested patient. The invention also relates to kit(s) suitable for carrying out the method(s) of the invention and their use.


Patent
Instituto Nacional Of Neurologia Y Neurocirugia Manuel Velasco Suarez, Instituto Mexicano Del Seguro Social and Instituto Nacional de Investigaciones Nucleares | Date: 2010-03-17

The purpose of the present invention is to demonstrate that semiconducting and non-biodegradable implants made with polypyrrole and polyethylenglycol copolymers and iodine-doped and plasma-synthesised pyrrole polymers, have a neuroprotector effect and induce the reconnection of the spinal cord after an injury; this effect was proved in a model involving a complete section of the spinal cord in rats; the results o the functional evaluation demonstrated 5 times greater recovery in animals implanted with the polypyrrole-polyethylenglycol copolymer compared with the control group which only underwent a complete section of the spinal cord; in addition, the functional recovery of the group with iodine-doped polypyrrole was ten times greater compared to the control group; in the histological study various inflammatory and immune cells were identified at the injury site in the three experimental groups with and without implants and the integration of the polymers in the nervous tissue of the spinal cord was also observed; finally, no respiratory, renal or skin infections, adverse effects or rejection of the biomaterials were found in any of the animals.


Lajud N.,Instituto Mexicano del Seguro Social | Torner L.,Instituto Mexicano del Seguro Social
Frontiers in Molecular Neuroscience | Year: 2015

Adverse early life experience decreases adult hippocampal neurogenesis and results in increased vulnerability to neuropsychiatric disorders. Despite that the effects of postnatal stress on neurogenesis have been widely studied in adult individuals, few efforts have been done to evaluate its immediate effects on the developing hippocampus. Moreover, it is not clear whether postnatal stress causes a differential impact in hippocampus development in male and female neonates that could be related to emotional deficits in adulthood. It has been proposed that the long term effects of early stress exposure rise from a persistent HPA axis activation during sensitive time windows; nevertheless the exact mechanisms and mediators remain unknown. Here, we summarize the immediate and late effects of early life stress on hippocampal neurogenesis in male and female rat pups, compare its later consequences in emotionality, and highlight some relevant mediator peptides that could be potentially involved in programming. © 2015 Lajud and Torner. This is an open-access article distributed under the terms of the Creative Commons Attribution License.


Jauregui Renaud K.,Instituto Mexicano Del Seguro Social
Multisensory Research | Year: 2015

Patients with an acquired sensory dysfunction may experience symptoms of detachment from self or from the environment, which are related primarily to nonspecific symptoms of common mental disorders and secondarily, to the specific sensory dysfunction. This is consistent with the proposal that sensory dysfunction could provoke distress and a discrepancy between the multi-sensory frame given by experience and the actual perception. Both vestibular stimuli and vestibular dysfunction can underlie unreal experiences. Vestibular afferents provide a frame of reference (linear and angular head acceleration) within which spatial information from other senses is interpreted. This paper reviews evidence that symptoms of depersonalization/derealization associated with vestibular dysfunction are a consequence of a sensory mismatch between disordered vestibular input and other sensory signals of orientation. © Copyright 2015 by Koninklijke Brill NV, Leiden, The Netherlands.


Garcia-de-Alba-Garcia J.-E.,Instituto Mexicano del Seguro Social
Medicina Oral, Patologia Oral y Cirugia Bucal | Year: 2011

Objectives: To develop and to evaluate a questionnaire of self-perception and self-care habits on oral health on a first level population. Methods: A descriptive observational studas perfored to validate a questionnaire on oral health self-perception (UISESS-B). After non-probabilistic sampling,94 users,30-59 years of age,with either diabetes mellitus 2,hypertension or obesity were included. Duration of disease was lesser than 10 years. Pearson's r, Cornbach's α, factorial analysis,chi-square and Snedecor's F tests were employed. Results:A Pearson's r of 0.7and Cronbach's α of 0.82was observed on the pre-post values of the global questionnaire. In the factorial analysis, the variance explained more than 60% for a first factor. Apunctuation of very high risk for the three groups with the scale UISESSS-B that coincides with the index CPO-D and the index UISESS-F was observed. Conclusions: The UISESS-B scale shows significant validity and reliability, suggestingits use as a sensitive ins-trument for the measurement of oral health in people with chronic illnesses such as diabetes,hypertension and obesity. © Medicina Oral S. L.


Velazquez J.R.,Instituto Mexicano del Seguro Social
Clinical reviews in allergy & immunology | Year: 2011

The development of the allergic airway disease conveys several cell types, such as T-cells, eosinophils, mast cells, and dendritic cells, which act in a special and temporal synchronization. Cellular mobilization and its complex interactions are coordinated by a broad range of bioactive mediators known as chemokines. These molecules are an increasing family of small proteins with common structural motifs and play an important role in the recruitment and cell activation of both leukocytes and resident cells at the allergic inflammatory site via their receptors. Trafficking and recruitment of cell populations with specific chemokines receptors assure the presence of reactive allergen-specific T-cells in the lung, and therefore the establishment of an allergic inflammatory process. Different approaches directed against chemokines receptors have been developed during the last decades with promising therapeutic results in the treatment of asthma. In this review we explore the role of the chemokines and chemokine receptors in allergy and asthma and discuss their potential as targets for therapy.


Vladislavovna Doubova Dubova S.,Instituto Mexicano del Seguro Social
Health and quality of life outcomes | Year: 2010

1) To design and validate indicators to measure the quality of the process of care that climacteric stage women receive in family medicine clinics (FMC). 2) To assess the quality of care that climacteric stage women receive in FMC. 3) To determine the association between quality of care and health-related quality of life (HR-QoL) among climacteric stage women. The study had two phases: I. Design and validation of indicators to measure the quality of care process by using the RAND/UCLA Appropriateness Method. II. Evaluation of the quality of care and its association with HR-QoL through a cross-sectional study conducted in two FMC located in Mexico City that included 410 climacteric stage women. The quality of care was measured by estimating the percentage of recommended care received (PRCR) by climacteric stage women in three process components: health promotion, screening, and treatment. The HR-QoL was measured using the Cervantes scale (0-155). The association between quality of care and HR-QoL was estimated through multiple linear regression analysis. The lowest mean of PRCR was for the health promotion component (24.1%) and the highest for the treatment component (86.6%). The mean of HR-QoL was 50.1 points. The regression analysis showed that in the treatment component, for every 10 additional points of the PRCR, the global HR-QoL improved 2.8 points on the Cervantes scale (coefficient -0.28, P < 0.0001). The indicators to measure quality of care for climacteric stage women are applicable and feasible in family medicine settings. There is a positive association between the quality of the treatment component and HR-QoL; this would encourage interventions to improve quality of care for climacteric stage women.


Barrera-Cruz A.,Instituto Mexicano del Seguro Social
Revista médica del Instituto Mexicano del Seguro Social | Year: 2013

Excess weight (overweight and obesity) is currently recognized as one of the most important challenges of public health in the world, given its size, speed of growth, and the negative effect on the population who suffers it. Overweight and obesity increases significantly the risk of chronic non-communicable diseases, and premature mortality, as well as the social cost of health. Today, Mexico has the second global prevalence of obesity in the adult population (30 %), which is ten times higher than Korea's or Japan's (4 %). Until 2012, 26 million Mexican adults were overweight, and 22 million, obese. This implies a major challenge for the health sector. Mexico needs to plan and implement strategies and cost-effective actions for the prevention and control of obesity in children, adolescents, and adults. Global experience shows that proper care of obesity and overweight demands to formulate and coordinate efficient multi-sectoral strategies for enhancing protective factors to health, particularly to modify individual behavior, family and community.

Loading Instituto Mexicano Del Seguro Social collaborators
Loading Instituto Mexicano Del Seguro Social collaborators